Can Dianthus Therapeutics (DNTH) Stay Undervalued Following Its $500 Million Stock Offering?
Dianthus Therapeutics Inc DNTH
$88.55
▼ -2.38%
($-2.16)
⬇️ Below Yest. Low
Open
$91.56
Prev Close
$90.71
Day Range
$88.34 – $92.89
52W Range
$32.22 – $117.88
Market Cap
$4.95B
Beta
1.99
EPS (TTM)
$-4.15
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-06-21 |
| Shares Out. | 54,670,000 |
| Website | dianthustx.com/ ↗ |
| Phone | 13026587581 |
| Employees | 92 |
| Revenue | $761,000 |
| Gross Profit | $761,000 |
| Net Income | -$50.2M |
| Free Cash Flow | -$155.7M |
| Total Assets | $1.21B |
| Total Liabilities | $41.2M |
| Equity | $1.17B |
About Dianthus Therapeutics Inc
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Dianthus Therapeutics Inc is a publicly traded company under the ticker symbol DNTH on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
22 analysts (2026-09-01)